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OBJECTIVE — The study investigated the effect of angiotensin receptor blockers (ARB) on
glucose homeostasis and inﬂammatory parameters in patients with impaired glucose tolerance
(IGT).
RESEARCH DESIGN AND METHODS — We prospectively studied the insulin sensi-
tivity index (ISI) and homeostasis model assessment–insulin resistance (HOMA-IR) in 13 obese
maleswithIGTandin13matchedcontrolsubjectswithnormalglucosetolerance(NGT)during
hyperglycemic testing over 90 min. Adiponectin, retinol-binding protein 4 (RBP4), and high-
sensitive C-reactive protein (hsCRP) were analyzed. Measurements were performed at baseline
andaftera4-weektreatmentwith160mg/dayvalsartan.TheresultsoftheIGTandNGTgroups
were compared.
RESULTS — At baseline, HOMA-IR (IGT 4.1  3 vs. NGT 2.3  1.0, P  0.01), hsCRP (IGT
3.9  1.9 vs. NGT 1.8  1 mg/l, P  0.05), and RBP4 (IGT 27.1  2.1 vs. NGT 24.0  2.0
ng/ml, P  0.05) were signiﬁcantly higher, whereas ISI (IGT 1.5  0.9 vs. NGT 1.8  1.2, P 
0.05) and plasma adiponectin (IGT 3.2  0.9, NGT 5.2  2.4 g/ml, P  0.05) were signiﬁ-
cantlylowerintheIGTgroupcomparedwiththeNGTgroup.UnderARB,therewasanincrease
in both groups of adiponectin (IGT 4.1  1.9 g/ml, NGT 6.3  2.9 g/ml, P  0.05) and an
increase in ISI (IGT 1.5  0.9 to 2.3  1 g/ml, NGT 1.8  1t o2 . 5 2 g/ml, P  0.05).
HOMA-IR(4.13to2.62;P0.01),hsCRP(3.91.9to1.81mg/l,P0.05),andRBP4
(27.1  2.1 to 22.1  1.8 ng/ml, P  0.01) decreased signiﬁcantly in the IGT group.
CONCLUSIONS — Insulin sensitivity and associated inﬂammatory factors improve under
ARB in IGT patients.
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I
nsulin resistance has a causal role in
type 2 diabetes, a crucial risk factor for
cardiovascular and renal disease (1).
Impaired glucose tolerance (IGT) repre-
sents an intermediate state of abnormal
glucose regulation between normal glu-
cose homeostasis and manifest diabetes.
IGTisdeﬁnedaselevated2-hplasmaglu-
cose concentration 140 and 200
mg/dl after a 75-g oral glucose load in an
oral glucose tolerance test (2). A combi-
nation of -cell dysfunction and insulin
resistancewithdecreasedinsulinsensitiv-
ity or responsiveness to the metabolic ac-
tion of insulin plays a pathogenetic role.
Insulin resistance is common in subjects
with visceral adiposity, hypertension, hy-
perglycemia, and dyslipidemia. Patients
withmetabolicsyndromehaveahighrisk
of developing frank diabetes (3).
Adiponectin is a fat-derived hormone
speciﬁcallyproducedandsecretedbyadi-
pocytes.Thisadipocytokineisconsidered
an important modulator of insulin sensi-
tivity in patients with IGT (4,5). Adi-
ponectin levels decrease in the obese,
which may be a contributing factor to in-
sulin resistance. Anti-inﬂammatory prop-
erties also have been attributed to
adiponectin. This is indicated by serum
concentrations of adiponectin, which are
inversely associated with inﬂammatory
markerssuchasC-reactiveprotein(CRP).
Retinol-binding protein 4 (RBP4) is an-
other adipocyte-secreted molecule and is
elevated in serum before development of
overt diabetes (6).
Theinteractionofthesedifferentmet-
abolic and inﬂammatory parameters in
IGThasnotbeenfullyclariﬁed.Ourstudy
investigates insulin sensitivity and associ-
ated risk factors focusing on obese sub-
jects with IGT. We tested the effect of a
short-term 4-week angiotensin receptor
blocker (ARB) treatment on glucose dis-





A total of 57 male adults with a waist cir-
cumference 102 cm were tested.
Screening included physical examination
and blood and urine chemistry. IGT was
diagnosed based on an oral glucose toler-
ance test (2). Smokers and patients with
known vascular, infectious, or inﬂamma-
tory diseases, micro- and macroalbumin-
uria, serum creatinine 1.2 mg/dl,
secondary forms of or uncontrolled hy-
pertension (greater than European Soci-
ety of Hypertension class 1), ongoing
medication with blockade of the renin-
angiotensin system (RAS), and diabetes
were excluded.
A total of 15 subjects had IGT, 3 sub-
jects had diabetes, and 39 subjects had
NGT. Thirteen subjects with IGT fulﬁlled
all inclusion criteria and completed the
entire study. We selected 13 tightly
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ments were taken using an automated
portable device at the beginning and end
of the study (Spacelabs Medical, Red-
mond, WA). Measurements of the study
parameters were performed at rest and
during hyperglycemic stress testing at
baseline (U1) and after a 4-week treat-
ment with valsartan (U2).
The study was approved by the Ethi-
calCommitteeoftheTechnicalUniversity
ofMunich.Everyparticipantgavewritten
informed consent. This investigator initi-
ated trial was conﬁrmed by the Federal
Institute for Drugs and Medical Devices
(BfArM, Germany) and registered by
the European Clinical Trials Database
(EudraCT, no. 2005-001278-28).
Hyperglycemic clamp
A modiﬁed clamp technique following
the De Fronzo protocol was used to
achieve a hyperglycemic level of a target
blood glucose between 160 and 180
mg/dl (7). Initially, the subjects re-
ceived an intravenous bolus of 1.5 ml
20%glucosesolution/kgtoraiseplasma
glucose acutely above 200 mg/dl.
Plasma glucose concentrations during
the procedure were monitored at 1-min
intervals (glucose analyzer, HITADO
Diagnostic Systems). When blood glu-
cose reached a level of 180 mg/dl, the
desired hyperglycemic plateau of 160
mg/dl and 180 mg/dl was maintained
by initiating an adjusted continuous in-
fusionof20%glucosedependingonthe
actual blood glucose concentration.
Once a steady state was reached and
maintained for over 90 min, laboratory
parameters were measured (Fig. 1). Se-
rum glucose, serum insulin, and C-
peptide were measured after a 12-h fast
at baseline.
Laboratory methods
Serum insulin concentrations were mea-
sured using electrochemiluminescence.
Adiponectin plasma concentrations were
determined by an enzyme-linked immu-
nosorbent assay. RBP4 was measured us-
ing the Human RBP4 Quantikine ELISA
Kit DRB400. All other measurements
were performed with routine laboratory
tests and methods certiﬁed by the Insti-
tuteofClinicalChemistry,TechnicalUni-
versity Munich, Germany. Insulin
sensitivity was quantiﬁed using the vali-
datedmodelofhomeostasismodelassess-
ment–insulin resistance (HOMA-IR) (8).
Insulin sensitivity index was calculated as
1/fasting serum insulin  fasting serum
glucose (9).
Statistical analysis
Data are given as means  SD for con-
tinuous variables or as a percentage in
categorical variables. Normal data dis-
tribution was conﬁrmed by the Kolmog-
orov-Smirnov test. Normally distributed
datawereanalyzedusingtheStudent’sttest
for comparisons at baseline and after
treatment with ARB. We used the Mann-
Whitney U test to analyze the differences
of time spent to undercut the target limit
of 180 mg/dl blood glucose for both
groups. All statistical analyses were per-
formed using the SPSS version 16.0 for
Windows.
RESULTS— Baseline characteristics
are shown in Table 1. There was no sig-
niﬁcant difference in age, BMI, waist
circumference, systolic and diastolic
blood pressure, fasting serum glucose,
triglycerides, and HDL cholesterol. A
total of 13 participants were treated
Figure 1—Experimental setting and course of blood glucose (mg/dl) during hyperglycemic stress
testing by intravenous glucose infusion for each group without ARB. A bolus (1.5 ml 20% glucose
solution/kg) was given to raise blood glucose acutely. Subsequently, as blood glucose reached a
level of 180 mg/dl, the desired hyperglycemic plateau of 160 mg/dl and 180 mg/dl was
maintained by the start of an adjusted continuous infusion of 20% glucose. There is a signiﬁcant
difference of the time duration to undercut a blood glucose value of 180 mg/dl with a signiﬁcantly
shorter time in the NGT group (Mann-Whitney U test; presented as box plots, P  0.001, Bon-
ferroni-adjusted P values).
Table 1—Baseline characteristics of the subjects according to the study groups
IGT group NGT group
n 13 13
Age (years) 50.0  13 50.6  10
BMI (kg/m
2) 31.1  6 33.5  4
Waist circumference (cm) 110.3  11 111.9  9
Ofﬁce systolic blood pressure (mmHg) 137  10 136  16
Ofﬁce diastolic blood pressure (mmHg) 85  68 8  13
Fasting serum glucose (mg/dl) 89  13 85  8
Serum triglycerides (mg/dl) 111  37 102  37
Serum HDL (mg/dl) 45  14 44  16
Data are means  SD.
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antagonists: four IGT; three NGT;
-blockers: three IGT, three NGT).
Duringhyperglycemia,meanbloodglu-
cose values of 170  9 mg/dl (IGT) and
171 7mg/dl(NGT)wereheldover90
min. The time required to reach steady-
state conditions within the targeted
blood glucose plateau was longer in the
IGT group (IGT 37.2  3 vs. NGT
15.8  2 min, P  0.05, Fig. 1). Under
ARB, there was no signiﬁcant difference
in the blood glucose proﬁles of both
study groups under clamp testing (Fig.
2). At baseline, HOMA-IR, RBP4, and
high-sensitive (hs)-CRP serum levels
were signiﬁcantly higher, whereas insu-
lin sensitivity index and plasma adi-
ponectin were signiﬁcantly lower for
the IGT group (Table 2). At baseline, in
both groups, there were no signiﬁcant
differences in ambulatory systolic (IGT
125  6 vs. NGT 123  1 mmHg, P 
0.86) and diastolic (IGT 77  2; NGT
77  3 mmHg, P  0.95) blood pres-
sure. However, there was a signiﬁcantly
higher reduction of systolic blood pres-
sure in the IGT group compared with
the NGT group (IGT 118  3 vs. NGT
121  4 mmHg, P  0.05) under ARB.
There was no signiﬁcant difference
between diastolic blood pressure re-
duction in either group (IGT 73  3 vs.
NGT 74  5 mmHg, P  0.11)
(Table 2).
Effects of ARB on insulin sensitivity
Under 4-week treatment with valsartan,
insulin sensitivity index increased signif-
icantly in both groups (IGT 1.5  1 vs.
2.31,P0.05;NGT1.81vs.2.5
2, P  0.05). HOMA-IR decreased signif-
icantly in the IGT group under ARB (IGT
4.13vs.2.62,P0.01;NGT2.3
1 vs. 1.6  1, P  0.016, Fig. 3). There
was a signiﬁcant reduction in A1C in the
IGTgroup(5.580.15vs.5.20.25%,
P  0.05), whereas no A1C changes were
noted in the control group (Table 2).
RBP4 decreased signiﬁcantly in the IGT
group (IGT 27.1  2.1 vs. 22.1  1.8
ng/ml, P  0.01; NGT 24.0  2.0 vs.
22.0  1.9, P  0.98). Fasting insulin
levels were reduced under valsartan in
both groups (IGT 16.6  11 vs. 13.2  8
mU/l, P  0.05; NGT 16.1  10 vs.
12.3  6, P  0.05). There was no differ-
ence in C-peptide levels in all groups
(Table 2).
Effects of ARB on inﬂammatory risk
markers
Plasma adiponectin levels increased sig-
niﬁcantly in both groups (IGT 3.2  1.0
vs. 4.1  1.9 g/ml, P  0.05; NGT
5.22.4vs.6.32.9,P0.05).hsCRP
levels decreased signiﬁcantly in the IGT
group (IGT 3.9  1.9 vs. 1.8  0.9 mg/l,
P  0.05; NGT 1.8  0.9 vs. 2.2  1.9,
P  0.89).
CONCLUSIONS — In obese males
with IGT, we found increased inﬂamma-
tory markers associated with a higher de-
gree of insulin resistance compared with
Figure 2—Blood glucose (mean values) (mg/dl) during hyperglycemic stress testing for each
group after 4-week treatment with valsartan.
Table 2—Insulin resistance parameters, inﬂammatory markers, and 24-h systolic and diastolic blood pressure of the subjects according to the
study groups with and without ARB
IGT group NGT group P IGT group  ARB NGT group  ARB
n 13 13 13 13
Adiponectin (g/ml) 3.2  0.9 5.2  2.4 0.05 4.1  1.9* 6.3  2.9*
HOMA-IR 4.1  3 2.3  1 0.01 2.6  2† 1.6  1
Insulin sensitivity index 1.5  0.9 1.8  1.2 0.05 2.3  1* 2.5  2*
Fasting (insulin) (mU/l) 16.6  11.2 16.1  10 0.05 13.2  8* 12.3  6*
C-peptide (nmol/l) 1.2  0.4 1.5  1 0.78 1.0  0.4 1.2  0.4
hsCRP (mg/l) 3.9  1.9 1.8  1 0.05 1.8  0.9* 2.2.  1.9
A1C (%) 5.58  0.2 5.29  0.2 0.01 5.20  0.3* 5.30  0.3
RBP4 (ng/ml) 27.1  2.1 24.0  2.0 0.05 22.1  1.8† 22.0  1.9
24-h systolic blood pressure (mmHg) 125  6 123  1 0.86 118  3* 121  4
24-h diastolic blood pressure (mmHg) 77  27 7  3 0.95 73  37 4  5
Data are means  SD, unless otherwise indicated. *P  0.05. †P  0.01.
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ment with valsartan improved insulin
sensitivity, RBP4, and A1C as chemical
features of insulin resistance. hsCRP and
adiponectin improved in the group of
subjects with IGT.
Improvement of insulin sensitivity
In IGT, defective early-phase and late in-
sulin secretion combined with muscle
and hepatic insulin resistance results in
prolonged hyperglycemia after a glucose
load. Our data conﬁrm pathophysiologi-
cal mechanisms, where the timeframe af-
ter glucose bolus averages about 20 min
longer than for the control group. After
treatment with valsartan, metabolic
changes are indicated by a decrease in in-
sulin resistance and an increase in adi-
ponectin. The reduction of time to reach
the targeted blood glucose 180 mg/dl
after glucose bolus within the IGT group
under ARB demonstrates an improve-
ment in early-phase insulin secretion and
reduction of insulin resistance. A sequen-
tial insulin scan between glucose bolus
and target value is advisable but was not
part of this study. Jin and Pan (10)
showed an improvement in glucose ho-
meostasis in type 2 diabetic patients by
lorsartan. The results of the Diabetes RE-
duction Assessment with ramipril and
rosiglitazone Medication (DREAM) trial
indicated favorable effects of RAS block-
ade with ramipril on glucose metabolism
(11).Mechanismsfortheimprovementof
glucose tolerance are complex. The inter-
action of RAS with peroxisome prolifera-
tor–activated receptor (PPAR)-	 affects
insulin sensitivity (12). Angiotensin II in-
hibits adipogenic differentiation of hu-
manadipocytesviatheAT1receptor(13).
Expression of angiotensin II–forming en-
zymes in adipose tissue correlates in-
versely with insulin sensitivity by
decreasedcirculatingadiponectin(14).In
vivo, the activation of the angiotensin 2
receptor and certain ARB induce adi-
ponectin in adipocytes, which is associ-
ated with improvement in insulin
sensitivity in murine adipocytes and
obese Zucker rats. ARB-induced adi-
ponectin stimulation is likely to be medi-
ated via PPAR-	 activation involving a
posttranscriptional mechanism (15). ARB
induce adipogenesis and PPAR-	 target
geneexpressioninhumanadipocytesand
increase adiponectin, which contributes
to the metabolic impact of this class of
drug. In humans, it is unclear whether
larger doses of ARB or longer treatments,
or both, may be required to activate
PPAR-	inadiposecells.Therelevancefor
theglucosemetabolismofthePPAR-	ag-
onist actions of the ARB on insulin sensi-
tivity in patients with IGT is unclear,
noting that effects are much greater in
cell-free systems than in intact cells or in
vivo (16). Another mechanism to discuss
is improvement of intra-islet blood ﬂow
regulatedbylocalactivityoftheRAS(17).
We have no knowledge of any upregula-
tion of the RAS through the temporary
hyperglycemia in patients with IGT. In
animal testing by the Zucker obese (fa/fa)
model of type 2 diabetes, an upregulation
afterglucoseloadwasnoted.Afteradmin-
istration of an ARB, islet blood ﬂow in-
creased insulin secretion and increased
-cell mass and normalization of islet
morphology (18). Changes in islet perfu-
sion may contribute to the delayed ﬁrst
phase of insulin response to glucose. The
enhancement of insulin signaling, possi-
bly additionally disturbed by angiotensin
II receptor cross-talk and insulin secre-
tion by the -cells, supports glucose de-
livery to insulin-sensitive tissue by
inhibiting the RAS, which may improve
intra-islet blood ﬂow and microcircula-
tion in skeletal muscle.
While in rats Juan et al. (19) demon-
strated increased insulin sensitivity upon
chronic angiotensin II infusion, we found
incontrastincreasedinsulinsensitivityby
ARB treatment in human subjects with
IGT. We know that angiotensin II exerts
itseffectsthroughtwodifferentreceptors,
the angiotensin type 1 receptor (AT1R)
and angiotensin type 2 receptor (AT2R).
WeknowthattheAT1receptoristhepre-
dominant receptor in the cardiovascular
system and mediates most of the deleteri-
ous effects of angiotensin II, such as vaso-
constriction,endothelialdamage,andcell
proliferation. The AT2 receptor is now
recognizedasthecounter-regulatorofthe
AT1 receptor, exerting mostly beneﬁcial
actions such as vasodilation, anti-
proliferation, and anti-inﬂammatory ef-
fects. Apart from species differences,
these contradicting results may be ex-
plained by the AT2R stimulation during
selective AT1 receptor blockade under
certain pathological conditions in which
theavailableangiotensinIIisredirectedto
the AT2 receptor.
Improvement of inﬂammatory risk
markers
Subclinicallow-gradeinﬂammationplays
an important role in the pathogenesis of
insulin resistance. Angiotensin II ad-
versely affects glucose metabolism by in-
creasing reactive oxygen species and
inducing subclinical inﬂammation. Ele-
vated CRP serum levels have been associ-
ated with cardiovascular disease and




inﬂuence interleukin-6 and CRP produc-
tion (21). It has been shown that CRP
suppresses adiponectin gene expression
partially through the phosphatidylinosi-
tol 3-kinase pathway, and decreased pro-
duction of adiponectin might represent a
mechanism by which CRP regulates insu-
lin sensitivity (22). Yuan et al. (23)
showed an elevation of hsCRP in patients
with IGT accompanied by the opposite
changes of adiponectin. In our study,
treatmentwithvalsartanimprovedhsCRP
and adiponectin concentrations. RBP4
hasbeenshowntocorrelatewiththemag-
nitudeofinsulinresistanceinlean,obese,
and diabetic subjects identifying associ-
ated cardiovascular risk factors (6). Our
data conﬁrm these ﬁndings for subjects
with IGT with signiﬁcantly higher RBP4
levels compared with matched control
subjects with NGT, indicating possible
beneﬁcial effects for the prevention of
diabetes.
Effect of RAS blockade on blood
pressure in IGT
Obesity is a major etiological factor in
prehypertension in which adipose tis-
sue activates the RAS. The Trial of Pre-
vention of Hypertension demonstrated
Figure 3—Insulin resistance deﬁned by
HOMA-IRwithandwithoutARBseparatelyfor
the NGT and IGT group.
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lays blood pressure exaggeration in pre-
hypertensive patients (24). Our study
included prehypertensive individuals,
deﬁned as having a systolic blood pres-
sure of 120–139 mmHg or diastolic
blood pressure of 80–89 mmHg, and
hypertensive individuals. The mean re-
duction in ambulatory systolic blood
pressure under valsartan treatment was
considerably higher in the IGT group
than the NGT group. These changes
may reﬂect an activated RAS in subjects
with insulin resistance.
We acknowledge the following lim-
itation of our experimental study: In
isolated IGT, the primary pathomecha-
nism is defective early-phase and late
insulinsecretioncombinedwithmuscle
and hepatic insulin resistance. An im-
portant additional pathomechanism is
also the reduced glucagon-like peptide
(GLP)-1 serum level (25). In our patient
group, we cannot exclude to a certain
extent a variance of the low GLP-1 lev-
els. In addition, since we investigated
insulin resistance during intravenous
glucose stress testing, the effects of in-
cretins (GLP-1, glucose-dependent in-
sulinotropic peptide) on intravenous
glucose load were not retrieved. This
importantandinterestingincretineffect
has to be taken into account in inter-
preting our results.
In conclusion, in patients with im-
pairedglucosetolerance,insulinsensitivity
andassociatedlow-gradeinﬂammationim-
prove after treatment with ARB. These ef-
fects may provide a rationale for early
pharmacological intervention aimed at
ameliorating diabetic and cardiovascu-
lar risk in subjects with metabolic
disease.
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